Swiss pharmaceutical company, Lonza, announced that its Pharma & Biotech segment is expanding its footprint for Parenteral Dosage Form development with a further build-out of its Drug Product Services (DPS). This investment will significantly expand both capability and capacity of DPS at the Stücki Science Park in Basel (CH) and will create more than 50 new positions. The expanded offering includes new capabilities for drug product process development.
DPS opened its laboratories in November 2016 with an initial focus on Formulation Development and Drug Product Analytical Development. This facility was recently granted a GMP license after a successful audit by Swissmedic allowing QC release and stability testing of drug products.
“This significant expansion represents an important milestone in Lonza’s evolution to become a fully integrated drug development partner. With the recent acquisition of Capsugel, combined with DPS’s excellence in parenterals, we offer a wide range of services to meet our customers’ drug product needs,” said Marc Funk, COO of Lonza’s Pharma & Biotech segment. “Our expansion in Basel also signals Lonza’s strong commitment to the local community.”
The DPS team provides a holistic approach to drug product development that anticipates and prevents problems early and helps ensure the product is optimal for manufacture, supply chain and patient use. The DPS team provides a complete portfolio of services for parenteral dosage forms including products for injection and infusion for intravenous, subcutaneous, and intraocular routes of administration.
These offerings also include specialized services, such as:
- Particulate identification, characterization and quantification
- Excipient and surfactant characterization
- Extractables and leachables assessment
- Container closure integrity testing